Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $2.54B |
| Gross Profit (TTM) | $2.43B |
| EBITDA | $1.56B |
| Operating Margin | 19.80% |
| Return on Equity | 14.00% |
| Return on Assets | 5.09% |
| Revenue/Share (TTM) | $5.82 |
| Book Value | $15.33 |
| Price-to-Book | 3.76 |
| Price-to-Sales (TTM) | 13.26 |
| EV/Revenue | 12.98 |
| EV/EBITDA | 19.21 |
| Quarterly Earnings Growth (YoY) | -46.30% |
| Quarterly Revenue Growth (YoY) | 16.50% |
| Shares Outstanding | $445.28M |
| Float | $417.46M |
| % Insiders | 6.49% |
| % Institutions | 87.33% |
Volatility is currently contracting
Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.
Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and increased scalability for higher-value transactions. The company is capitalizing on inflows into the biopharma sector, with a strategic shift toward development-stage assets that yield higher IRRs and a strong track record of regulatory approvals. Several positive catalysts are coming up. All are poised to drive incremental royalty growth.
Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728 million operating cash flow, reinforcing the core compounder thesis. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth despite headwinds like Promacta erosion and IRA-related pressure.
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RPRX and any ticker you trade — then tracks every position and per-strategy win rate.
